Clinical Trial

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

Name: Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors — clinical trial record (NCT07662018)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.

Trial Details

NCT Number	NCT07662018
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Prospective Observational Study, Gemcitabine, Docetaxel, Melphalan, Carboplatin, Stem Cell Transplantation, Pediatric Relapsed, Refractory Germ
Enrollment	30 participants
Start Date	2026-06-05
Primary Completion	2031-12-31 (estimated)
Study Completion	2033-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-23